Correlation Between Vitrolife and Ascelia Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Vitrolife and Ascelia Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vitrolife and Ascelia Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vitrolife AB and Ascelia Pharma AB, you can compare the effects of market volatilities on Vitrolife and Ascelia Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vitrolife with a short position of Ascelia Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vitrolife and Ascelia Pharma.

Diversification Opportunities for Vitrolife and Ascelia Pharma

-0.47
  Correlation Coefficient

Very good diversification

The 3 months correlation between Vitrolife and Ascelia is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding Vitrolife AB and Ascelia Pharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ascelia Pharma AB and Vitrolife is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vitrolife AB are associated (or correlated) with Ascelia Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ascelia Pharma AB has no effect on the direction of Vitrolife i.e., Vitrolife and Ascelia Pharma go up and down completely randomly.

Pair Corralation between Vitrolife and Ascelia Pharma

Assuming the 90 days trading horizon Vitrolife AB is expected to under-perform the Ascelia Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Vitrolife AB is 2.23 times less risky than Ascelia Pharma. The stock trades about -0.13 of its potential returns per unit of risk. The Ascelia Pharma AB is currently generating about 0.31 of returns per unit of risk over similar time horizon. If you would invest  211.00  in Ascelia Pharma AB on September 4, 2024 and sell it today you would earn a total of  75.00  from holding Ascelia Pharma AB or generate 35.55% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Vitrolife AB  vs.  Ascelia Pharma AB

 Performance 
       Timeline  
Vitrolife AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Vitrolife AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.
Ascelia Pharma AB 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Ascelia Pharma AB are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain technical and fundamental indicators, Ascelia Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

Vitrolife and Ascelia Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Vitrolife and Ascelia Pharma

The main advantage of trading using opposite Vitrolife and Ascelia Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vitrolife position performs unexpectedly, Ascelia Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ascelia Pharma will offset losses from the drop in Ascelia Pharma's long position.
The idea behind Vitrolife AB and Ascelia Pharma AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Complementary Tools

Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Global Correlations
Find global opportunities by holding instruments from different markets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.